CARGO Therapeutics Reports Business Updates and Third Quarter 2023 Results
13 déc. 2023 16h05 HE
|
Cargo Therapeutics, Inc.
SAN MATEO, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell...
CARGO Therapeutics Announces Scientific Advisory Board
06 déc. 2023 08h05 HE
|
Cargo Therapeutics, Inc.
SAN MATEO, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CRGX), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell...
CARGO Therapeutics Announces Pricing of Initial Public Offering
09 nov. 2023 20h07 HE
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Announce Pricing of IPO
CARGO Therapeutics Announces Appointment of Ginna Laport, MD, as Chief Medical Officer
17 oct. 2023 09h05 HE
|
CARGO Therapeutics, Inc.
— Accomplished clinical leader with significant expertise in hematology/oncology drug development and a track record of advancing multiple modalities of cancer therapeutics — SAN MATEO, Calif., Oct. ...
CARGO Therapeutics Announces Appointment of Michael Ports, PhD, as Chief Scientific Officer
12 sept. 2023 09h05 HE
|
CARGO Therapeutics, Inc.
– Scientific leader with multi-company cell therapy drug development experience spanning early discovery initiatives through late-stage development – SAN MATEO, Calif., Sept. 12, 2023 (GLOBE...
CARGO Therapeutics Appoints Biotech Life Sciences Leaders to Board of Directors
24 août 2023 09h05 HE
|
CARGO Therapeutics, Inc.
– Board of Director appointments follow the Company’s recent launch and $200 million Series A financing in March 2023 – – Appointments include industry veterans John Orwin as Chairman, David Lubner...
CARGO Therapeutics to Present at the Jefferies Global Healthcare Conference
31 mai 2023 09h05 HE
|
CARGO Therapeutics, Inc.
SAN MATEO, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a biotechnology company advancing a next generation of CAR T-cell therapies for cancer, today announced that...
CARGO Therapeutics Raises $200 Million in Oversubscribed, Upsized Series A Financing to Advance its Pipeline of Next Generation CAR T-Cell Therapies
01 mars 2023 09h30 HE
|
CARGO Therapeutics, Inc.
– Series A financing co-led by Third Rock Ventures, RTW and Perceptive Xontogeny Venture Fund, and includes new investors Nextech, Janus Henderson Investors, Ally Bridge Group, Wellington Management,...